As a leading CRO, PRA is transforming clinical trials through our people, innovation and operational transparency. With 5,000+ employees in 30+ countries, PRA provides a full suite of services across all phases. We have conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 40+ drugs marketed across several therapeutic areas.
Since our inception in 1976, we have amassed a level of expertise that enables us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. PRA clients benefit from our strategic investment in key therapeutic programs and research areas, including neurology/psychiatry, oncology/hematology, infectious diseases, biosimilar products, cardio-metabolic diseases, and rare diseases.
PRA’s advanced technological tools and finely tuned systems ensure seamless delivery and transparency throughout our organization. Our dynamic services and forward-thinking approach to drug development programs are making a difference to healthcare patients worldwide.